Evidence map›Paper›PMID 27183822›Full record

ArticleBMC medicine2016

Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study.

Helen A Fletcher, Ali Filali-Mouhim, Elisa Nemes, Anthony Hawkridge, Alana Keyser, Samuel Njikan, Mark Hatherill, Thomas J Scriba, Brian Abel, Benjamin M Kagina and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Predicting Pediatric Tuberculosis: The Need for Age-Specific Host Biosignatures.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. A 2-Dose AERAS-402 Regimen Boosts CD8Frontiers in immunology · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Tuberculosis susceptibility and protection in children.The Lancet. Infectious diseases · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Helen A FletcherLondon School of Hygiene & Tropical Medicine, London, UK.
Ali Filali-MouhimDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Elisa NemesSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Anthony HawkridgeSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Alana KeyserSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Samuel NjikanSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Mark HatherillSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Brian AbelSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Benjamin M KaginaSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Ashley VeldsmanSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Nancy Marín AgudeloGrupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia.
Gilla KaplanPublic Health Research Institute, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
Gregory D HusseySouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Rafick-Pierre SekalyDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Willem A HanekomSouth African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. willem.hanekom@gatesfoundation.org.
BCG study team

Funding

Protective immunity induced by newborn BCG vaccinationR01AI065653 · NIAID · UNIVERSITY OF CAPE TOWN · PI HANEKOM, WILLEM ALBERT · 2005 to 2009
$2.5M
NIAID NIH HHS R01 AI065653NIAID NIH HHS R01-AI065653
6 · The paper itself

Abstract

backgroundAn incomplete understanding of the immunological mechanisms underlying protection against tuberculosis (TB) hampers the development of new vaccines against TB. We aimed to define host correlates of prospective risk of TB disease following bacille Calmette-Guérin (BCG) vaccination.

methodsIn this study, 5,726 infants vaccinated with BCG at birth were enrolled. Host responses in blood collected at 10 weeks of age were compared between infants who developed pulmonary TB disease during 2 years of follow-up (cases) and those who remained healthy (controls).

resultsComprehensive gene expression and cellular and soluble marker analysis failed to identify a correlate of risk. We showed that distinct host responses after BCG vaccination may be the reason: two major clusters of gene expression, with different myeloid and lymphoid activation and inflammatory patterns, were evident when all infants were examined together. Cases from each cluster demonstrated distinct patterns of gene expression, which were confirmed by cellular assays.

conclusionsDistinct patterns of host responses to Mycobacterium bovis BCG suggest that novel TB vaccines may also elicit distinct patterns of host responses. This diversity should be considered in future TB vaccine development.

Indexed as

Adjuvants, ImmunologicBCG VaccineCase-Control StudiesFemaleGene Expression Regulation, BacterialHumansInfantInfant, NewbornMaleProspective StudiesTuberculosisVaccinationAdjuvants, ImmunologicBCG VaccineCorrelates of riskSystems biologyTuberculosisVaccine

Identifiers

PMID27183822
PMCPMC4869393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.